Suppliers and packagers for JANTOVEN

JANTOVEN

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Upsher Smith Labs	JANTOVEN	warfarin sodium	TABLET;ORAL	040416	ANDA	Upsher-Smith Laboratories, LLC	0832-1211-00	100 TABLET in 1 BOTTLE (0832-1211-00)	2010-02-23
Upsher Smith Labs	JANTOVEN	warfarin sodium	TABLET;ORAL	040416	ANDA	Upsher-Smith Laboratories, LLC	0832-1211-01	100 BLISTER PACK in 1 CARTON (0832-1211-01) / 1 TABLET in 1 BLISTER PACK (0832-1211-89)	2010-02-23
Upsher Smith Labs	JANTOVEN	warfarin sodium	TABLET;ORAL	040416	ANDA	Upsher-Smith Laboratories, LLC	0832-1211-10	1000 TABLET in 1 BOTTLE (0832-1211-10)	2010-02-23
Upsher Smith Labs	JANTOVEN	warfarin sodium	TABLET;ORAL	040416	ANDA	Upsher-Smith Laboratories, LLC	0832-1212-00	100 TABLET in 1 BOTTLE (0832-1212-00)	2010-02-23
Upsher Smith Labs	JANTOVEN	warfarin sodium	TABLET;ORAL	040416	ANDA	Upsher-Smith Laboratories, LLC	0832-1212-01	100 BLISTER PACK in 1 CARTON (0832-1212-01) / 1 TABLET in 1 BLISTER PACK (0832-1212-89)	2010-02-23

Suppliers for the Pharmaceutical Drug: Jantoven

Last updated: July 29, 2025

Introduction

Jantoven, the brand name for warfarin sodium, is a critical anticoagulant medication used globally to prevent and treat thromboembolic disorders. Its broad therapeutic utility spans atrial fibrillation, deep vein thrombosis, pulmonary embolism, and prosthetic heart valve management. Ensuring a reliable supply of Jantoven is paramount for healthcare systems, given its life-saving potential. This analysis offers a comprehensive overview of the primary suppliers manufacturing Jantoven, scrutinizes their production capacities, regulatory statuses, and the strategic landscape defining its global availability.

Pharmaceutical Manufacturers of Jantoven (Warfarin Sodium)

1. Bristol-Myers Squibb (BMS)

Bristol-Myers Squibb originally developed warfarin in the 1940s. Although BMS no longer markets Jantoven under that name directly, it holds significant patent rights and manufacturing expertise related to warfarin compounds, primarily through its legacy portfolio. The original formulation of Jantoven was developed by BMS, which dominated the market in the early years. Currently, BMS’s intellectual property rights license other generic manufacturers to produce warfarin sodium formulations.

2. Manufacturers of Branded Jantoven

Jantoven is predominantly marketed in the United States by Bristol-Myers Squibb. However, the proprietary stand-alone formulation is increasingly supplied by generic manufacturers since patent expiration. The branded Jantoven remains a reference product used for bioequivalence and regulatory purposes.

3. Major Generic Manufacturers

Following patent expiry, several pharmaceutical companies have entered the market, producing generic warfarin sodium tablets comparable to Jantoven. Key players include:

• Mylan (now part of Viatris): A significant supplier of generic warfarin, supplying 1 mg, 3 mg, 5 mg, 2 mg, 4 mg, and 10 mg tablets to multiple markets globally.

• Teva Pharmaceutical Industries: A major Israeli-based manufacturer with a widespread portfolio of generic anticoagulants, including warfarin sodium.

• Sandoz (Novartis): Sandoz offers generic warfarin formulations in various strengths, supplying numerous countries, especially in Europe and Latin America.

• Dr. Reddy's Laboratories: An India-based manufacturer that produces generic warfarin, extending access in emerging markets.

• Pfizer: Though more involved with other anticoagulants, Pfizer has historically licensed or developed warfarin formulations for specific markets.

4. Other Notable Suppliers

• Lupin Limited: Indian pharmaceutical company manufacturing warfarin sodium tablets for domestic and export markets.

• Sun Pharmaceutical Industries: Also offers generic versions, predominantly in the Asian and African markets.

• Pfizer and Walgreens Boots Alliance: Some regional markets rely on Pfizer and Walgreens for distribution of warfarin-based products, including Jantoven equivalents.

5. Contract Manufacturing and Supply Chain Dynamics

Many generic companies outsource production to Contract Manufacturing Organizations (CMOs) such as Hikma Pharmaceuticals or Aurobindo Pharma, expanding the supply chain and ensuring competitive pricing and capacity flexibility. This approach increases drug availability but introduces variability in supply reliability, especially amidst global disruptions like pandemics or geopolitical tensions.

Regulatory and Market Dynamics

1. Approval and Compliance

In the United States, Jantoven’s formulations and generics must meet stringent FDA regulations, including bioequivalence standards, stability testing, and Good Manufacturing Practice (GMP) compliance. Many of the generic manufacturers have received FDA approval for their warfarin products, enabling broader distribution.

Internationally, regulatory bodies such as the European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, and local agencies in India, China, and Latin America approve warfarin generics aligned with global standards, ensuring supply chain stability.

2. Patent Status and Market Exclusivity

The original patent on warfarin sodium expired in various markets decades ago, leading to a proliferation of generics. Nonetheless, regulatory exclusivities in certain territories or for specific formulations can temporarily limit competition. As patents lapse, supply tends to increase, and pricing becomes more competitive.

3. Supply Chain Challenges

The production of warfarin is not particularly complex chemically; however, issues such as raw material sourcing, manufacturing capacity constraints, and compliance with regulatory standards significantly influence supply stability. Recent global supply chain interruptions, notably during COVID-19, underscored vulnerabilities in sourcing active pharmaceutical ingredients (APIs) from specific regions.

Global Market Overview and Supply Security

The supply of Jantoven and warfarin generics remains concentrated among prominent international pharmaceutical firms and regional manufacturers. Countries with robust pharmaceutical sectors (e.g., India, China, US, Europe) predominantly supply warfarin via licensed manufacturers. These firms’ strategic alliances, patent statuses, and manufacturing capacities significantly impact availability.

Emerging markets depend largely on Indian, Chinese, and some Eastern European manufacturers, with local distributors often relying on imported generics. The geopolitical landscape, trade policies, and patent litigations continue to shape the competitive environment.

Key Supply Challenges and Considerations

• Quality Assurance: Ensuring consistent potency, stability, and bioequivalence across batches.

• Regulatory Compliance: Navigating diverse regional approval processes and standards.

• Raw Material Dependency: Over-reliance on specific chemical suppliers for warfarin’s API can threaten supply stability.

• Market Competition: Intense generic competition can drive pricing and supply stability, but can also lead to shortages if manufacturing issues arise.

• Manufacturing Capacity: The capacity alignment among suppliers must match global demand to prevent shortages.

Conclusion

The supply landscape for Jantoven primarily revolves around a mix of originator and generic pharmaceutical manufacturers, with several established players providing stable, regulated supplies across different regions. While the original patent has expired, robust manufacturing infrastructure, regulatory compliance, and global supply chain management are critical to ensuring continuous availability. The dominance of Indian and Chinese manufacturers in this sector underscores the importance of regional manufacturing capacity and regulatory environments in supporting the global supply of warfarin-based anticoagulants.

---

Key Takeaways

• The original Jantoven brand is primarily supplied in the U.S. by Bristol-Myers Squibb, but most markets now rely on generic equivalents produced by multiple manufacturers.

• Major global suppliers include Mylan (Viatris), Teva, Sandoz, Lupin, and Sun Pharma, with many leveraging contract manufacturing.

• Expiry of patents has increased competition, but supply stability depends on manufacturing quality, raw material sourcing, and regulatory adherence.

• Regional differences in approval and regulatory standards influence market availability and supply chain resilience.

• Ongoing supply chain disruptions highlight the need for diversified manufacturing sources and strategic inventory management.

---

FAQs

1. Are all warfarin sodium tablets equivalent to Jantoven?
Yes, regulatory agencies require generic warfarin formulations to demonstrate bioequivalence to the reference product, ensuring comparable efficacy and safety.

2. Which countries are the largest producers of warfarin?
India and China are leading producers of generic warfarin APIs and tablets, supplying both domestic and international markets.

3. How does patent expiration affect the supply of Jantoven?
Patent expiration allows multiple manufacturers to produce generic versions, increasing supply and reducing prices, but the original Jantoven brand may still be available in certain markets.

4. What are the main challenges in sourcing warfarin globally?
Key challenges include raw material availability, manufacturing capacity, regulatory hurdles, and supply chain disruptions, especially during global crises.

5. Is there ongoing innovation to replace warfarin?
Newer oral anticoagulants (NOACs), such as rivaroxaban and apixaban, are increasingly replacing warfarin in some indications, potentially impacting warehousing and supply priorities for warfarin.

---

References

1. U.S. Food and Drug Administration (FDA). Approved Drug Products: Warfarin Sodium.
2. European Medicines Agency (EMA). Warfarin Summary of Product Characteristics.
3. MarketsandMarkets. Global Anticoagulants Market Report.
4. IQVIA. The World Preview 2022: Market Dynamics of Warfarin and Its Generic Competitors.
5. WHO Essential Medicines List. Warfarin.